The big-cap biotech is the traditional kick-off presentation at this closely followed conference, and this year, the company set a high bar for its competitors with strong financial guidance (including a bullish 2017 forecast for the first time) and positive psoriasis results from studies involving its experimental drug apremilast.
Celgene shares rose more than 4% to $85.73 on Monday and the stock was up again in Tuesday's pre-market session, bolstered by some analyst upgrades.
Gilead Sciences (GILD - Get Report) and Biogen Idec (BIIB - Get Report) also presented at the J.P. Morgan conference on Monday. While both offered confident outlooks for the coming year, Celgene was a standout. Amgen (AMGN - Get Report) presents at the conference later today.Read a lot more about Celgene's outlook and the way investors and others reacted to the company's J.P. Morgan presentation on Twitter with this Appeering conversation thread: -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.